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OBJECTIVES The purpose of this study was to determine whether human neutrophils express an
endothelial-type nitric oxide synthase (eNOS), and to study the effect of tumor necrosis
factor-alpha (TNF-alpha) on its expression.
BACKGROUND Several studies have demonstrated the presence of a constitutively expressed nitric oxide
synthase (NOS) in neutrophils. Cardiovascular disease is characterized by increased levels of
plasma TNF-alpha, a cytokine that has demonstrated eNOS messenger ribonucleic acid
(mRNA) destabilization in cultured endothelial cells.
METHODS Neutrophils were obtained from healthy volunteers and from patients with acute myocardial
infarction (AMI).
RESULTS Human neutrophils express eNOS mRNA and eNOS protein. Stimulation of neutrophils
with TNF-alpha decreased eNOS protein expression by reducing eNOS mRNA stabiliza-
tion. In the present study, we also show that the cytosol of human neutrophils contains
proteins that bind to a specific region within the 39-untranslated region (39-UTR) of eNOS
mRNA. Tumor necrosis factor-alpha increased the binding of the cytosolic proteins to the
39-UTR of eNOS mRNA. Simvastatin reduced the TNF-alpha–related binding activity of
neutrophil cytosolic proteins to eNOS mRNA, which was associated with its protective effect
on eNOS protein expression. The in vivo reproduction of the in vitro findings was performed
in neutrophils obtained from patients with AMI and showed a diminished expression of
eNOS protein, which was associated with increased binding of the cytosolic proteins.
CONCLUSIONS These observations demonstrate that human neutrophils express eNOS, which is downregu-
lated by TNF-alpha and during AMI. This effect is associated with increased binding of
neutrophil cytosolic proteins to the 39-UTR of eNOS mRNA. (J Am Coll Cardiol 2001;37:
800–7) © 2001 by the American College of Cardiology
Nitric oxide (NO) is released from the endothelium through
the activity of an initially defined constitutive enzyme called
“endothelial-type nitric oxide synthase” (eNOS) (1–3). It
has recently been shown that several pathophysiologic
stimuli, including cytokines, can reduce eNOS expression at
a post-transcriptional level (4,5). The loss of endothelium-
derived NO results in vascular abnormalities, including
vasoconstriction, smooth muscle cell proliferation and ad-
hesion of blood elements to the vessel wall (1,3,6). There-
fore, a decreased expression of eNOS may contribute to the
development of cardiovascular disease, including acute myo-
cardial infarction (AMI), in which the presence of cytokines
(i.e., tumor necrosis factor-alpha [TNF-alpha]) and a de-
fective production of endothelium-derived NO with a
reduction of eNOS expression have been reported (7–9).
Interestingly, there is growing evidence that the hydroxy-
methyl glutaryl coenzyme A reductase inhibitor simvastatin
reverses the downregulation of eNOS expression induced by
oxidized low density lipoprotein in endothelial cells under
cholesterol-clamped conditions (10,11). This occurs by
eNOS messenger ribonucleic acid (mRNA) destabilization
through a still unknown mechanism (10).
Several studies have shown that protein molecules control
mRNA stability by binding to specific sequences contained
in each mRNA (12,13). Some of these sequences have been
identified within the 39-untranslated region (39-UTR) of
the mRNAs (12). We recently demonstrated that bovine
endothelial cells contain cytosolic proteins that form com-
plexes with the in vitro–transcribed 39-UTR of eNOS
mRNA, which is associated with reduced expression of
eNOS protein (14).
Human neutrophils also produce NO through the activity
of a constitutive NOS (15,16). Several studies support the
importance of NO released by neutrophils to inhibit their
adhesion to the endothelium and to inhibit the aggregation
of neighboring platelets (17,18). Although the factors reg-
ulating expression of eNOS in the endothelium have been
widely investigated, little is known about the regulation of
the one expressed by neutrophils.
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In the present study, we have analyzed whether the
constitutive NOS isoform present in human neutrophils is
an endothelial-like NOS and whether these cells contain
cytosolic proteins that interact with the 39-UTR of eNOS
mRNA, as described in bovine endothelial cells. In addition,
we have studied the role of TNF-alpha in the expression of
the aforementioned constitutive NOS isoform and the
binding of cytosolic proteins to 39UTR of eNOS mRNA.
Because simvastatin has been shown to stabilize eNOS
mRNA in the endothelium (10,11), we used this drug to
analyze the correlation between the binding of neutrophil
cytosolic proteins to eNOS mRNA and the level of eNOS
protein expression.
In a second set of experiments, we studied the level of
eNOS protein in neutrophils obtained from patients with
AMI, a pathologic condition where the level of TNF-alpha
is considered to be increased (7,19).
METHODS
Human neutrophil isolation. Human neutrophils were
isolated from the peripheral blood of 15 healthy donors (25
to 40 years old) who had not ingested any drug for at least
two weeks before the study. Isolation and manipulation of
neutrophils were always performed under sterile and
endotoxin-free conditions. The neutrophils were isolated by
Ficoll/Hypaque centrifugation, as previously described
(6,18). The neutrophils were 95% pure and 98% viable, as
determined by exclusion of trypan blue stain. Neutrophils
were resuspended in RPMI 1640 medium, supplemented
with 0.25% bovine serum albumin, 5 mmol/liter glutamine,
2 3 1025 mg/liter penicillin and 2 3 1025 mg/liter
streptomycin (5 3 106 neutrophils/ml). The neutrophils
were then stimulated with TNF-alpha (500 U/ml).
Determination of eNOS protein expression. Endothelial-
type NOS protein expression in human neutrophils was
analyzed by Western blotting, as previously described
(20,21). Human neutrophils were incubated in the presence
and absence of TNF-alpha (500 U/ml). The neutrophils
were then lysed in Laemmli buffer containing
2-mercaptoethanol (22). Proteins (10 mg/lane) were sepa-
rated on denaturing sodium dodecyl sulfate/10% polyacryl-
amide gels, as previously described (14,21). A parallel gel
with identical samples was run and stained with Commassie
blue to compare the intensities of the protein bands.
Western blot analysis was performed with a specific mono-
clonal antibody against eNOS (Transduction Laboratories,
Lexington, United Kingdom), as previously reported
(14,21). Prestained protein markers were used for molecular
mass determinations.
Northern blot analysis. Isolated neutrophils were incu-
bated in the presence and absence of TNF-alpha (500 U/ml).
The experiments were performed in the presence of the
transcriptional inhibitor 5,6-dichloro-1-2-D-ribofuranosyl-
benzimidazole (DRB; Calbiochem, La Jolla, California).
Total RNA was isolated according to the method of
Chomczynski and Sacchi (23). Northern blot analysis of 20
mg/sample total RNA was performed as previously de-
scribed, using as a complementary deoxyribonucleic acid
(cDNA) probe the radiolabeled UTR-large (L) RNA (see
later discussion) (500,000 cpm/ml) (14). We also used a
probe encoding glyceraldehyde-3-phosphate dehydrogenase
as a control for loading.
Plasmids and in vitro transcription. Oligonucleotides
complementary to bovine eNOS cDNA (GenBank acces-
sion no. BTNIOXSY) were purchased from Bio-synthesis,
Inc. (Lewisville, Texas). The pNOS-UTR of plasmids was
made as previously reported (14). Oligonucleotide 1 (59-
GGATCTAGAACGCTATCACGAGGACATT-39)
and oligonucleotide 2 (59-AGGAAGCTTAGTAGGTC-
TCCTAACTTCTG-39) were used to produce the pNOS–
UTR-L, a fragment covering 166 bases of the coding region
and 393 bases of the 39-UTR of eNOS cDNA (Fig. 1) by
reverse transcriptase polymerase chain reaction (RT-PCR).
The amplification products were purified after agarose gel
electrophoresis, subjected to restriction endonuclease diges-
tion with Xba I and HindIII and ligated to PGEM4Z to
create pNOS–UTR-L.
Oligonucleotide 3 (59-GTTGGATCCCCTGTACTA-
TCTCACCCT-39) and oligonucleotide 2 were used to
create pNOS–UTR-small (S), as previously described (14).
To make plasmid pNOS–UTR-UC (rich in uridine and
cytidine nucleotides), pNOS–UTR-S was cut with Acs I. To
make pNOS–UTR-AU (rich in adenine and uridine nucle-
Abbreviations and Acronyms
AMI 5 acute myocardial infarction
cDNA 5 complementary deoxyribonucleic acid
CK 5 creatine kinase
DRB 5 5,6-dichloro-1-2-D-
ribofuranosylbenzimidazole
eNOS 5 endothelial-type nitric oxide synthase
mRNA 5 messenger ribonucleic acid
NO 5 nitric oxide
NOS 5 nitric oxide synthase
TNF-alpha 5 tumor necrosis factor-alpha
39-UTR 5 39-untranslated region
Figure 1. Endothelial-type NOS RNA probes used in gel mobility shift
assays. The diagram shows the different fragments of the 39-UTR from
eNOS mRNA used in this study. The entire eNOS mRNA is not drawn
to scale. 39-UTR 5 39-untranslated region; eNOS 5 endothelial-type
nitric oxide synthase; mRNA 5 messenger ribonucleic acid; nt 5 nucle-
otide.
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otides), Acs I–linearized pNOS–UTR-S was purified by
agarose gel electrophoresis and religated. Figure 1 represents
the different probes containing the different segments of the
39-UTR of eNOS mRNA.
To produce single-stranded RNA, the plasmids were
linearized with the corresponding restriction enzyme and
transcribed with SP6 or T7 RNA polymerase. Radiolabeled
RNA was produced according to the manufacturer’s recom-
mendations (Promega Biotech, Madison, Wisconsin) with
32P-CTP (CTP that is attached to radiolabeled phosphate)
(109 cpm/mg; Amersham Iberica, Madrid, Spain).
Band-shift assays. The neutrophils were incubated with
TNF-alpha (500 U/ml) for different periods. Then the
neutrophils were immediately centrifuged, washed twice in
ice-cold phosphate-buffered saline, resuspended in hypo-
tonic buffer (25 mmol/liter Tris-hydrochloride [pH 7.9],
0.5 mmol/liter EDTA and 1 mmol/liter phenilmethylsul-
fonyl fluoride [PMSF] and lysed by four cycles of freezing
and thawing, followed by centrifugation at 12,000 g at 4°C
for 15 min. The supernatant was removed, supplemented
with glycerol (10% final concentration) and frozen at
280°C until use. As previously reported (14), cytoplasmic
lysates of human neutrophils (10 mg) were incubated with
different radiolabeled RNA probes (5 to 10 3 104 cpm, ;1
ng RNA) in 15 mmol/liter HEPES (pH 7.9), 10 mmol/liter
KCl, 5 mmol/liter Cl2Mg, 1 mmol/liter dithidthretrol
(DTT), 1 mg/ml yeast tRNA (transfer RNA), 40 U RNAsin
(Promega Biotech, Madison, Wisconsin) and 10% glycerol
in a total volume of 15 ml for 10 min at 25°C. Afterwards,
20 U of RNase T1 per reaction (Gibco-BRL, Eggenstein,
Germany) was added, and the reaction mixtures were
incubated for 30 min at 37°C. The samples were electro-
phoresed on 4% native polyacrylamide gel, dried and auto-
radiographed with Kodak X-OMAT-S film.
Patient group. Eight consecutive patients (7 men and 1
woman) with AMI admitted in the Coronary Care Unit and
Emergency Unit of Fundacio´n Jime´nez Dı´az were investi-
gated. Acute MI was diagnosed on the basis of the classic
criteria of prolonged chest pain accompanied by serial
changes on the standard 12-lead electrocardiogram, as well
as raised serum creatine kinase (CK) (more than twice the
upper limit of the normal value measured in the biochem-
istry laboratory) and CK-MB (.10% total CK). The mean
age of the patients was 57 6 4 years (range 39 to 80). None
of the patients was taking any anti-inflammatory agent,
except for aspirin (200 mg/day). The control group included
eight volunteers from the hospital staff (mean age 50 6 6
years [range 33 to 70]).
The criteria for enrollment was hospital admission within
24 h after the onset of chest pain. The criteria for exclusion
were a previous episode of acute coronary syndrome and
previous treatment with statins. The present study did not
include patients or control subjects with a history of neo-
plastic, infectious or autoimmune disease or any surgical
procedure within the preceding six months. All subjects
gave fully informed consent, and the study was approved by
the Ethics Committee of Fundacio´n Jime´nez Dı´az.
Blood was obtained on hospital admission, and the
neutrophils were isolated and immediately lysed and frozen
at 280°C for determination of the level of eNOS expression
and the presence of cytosolic proteins that bind to the
39-UTR of eNOS mRNA.
Determinations of TNF-alpha. Tumor necrosis factor-
alpha was measured in plasma obtained from volunteers and
patients with AMI by using an enzyme-linked immunosor-
bent assay (ELISA) kit (Quantikine HS human TNF-
alpha, R&D Systems, Oxon, United Kingdom). The intra-
and interassay variabilities of the ELISA kit were 14.4% and
18.7%, respectively. The sensitivity of this kit is ,0.18 pg/ml.
Statistical methods. Unless otherwise stated, each study
was performed in a minimum of six different experiments.
Densitometric results of both Northern and Western blots
were expressed as the mean value 6 SEM. Comparisons
were performed by analysis of variance. The Bonferroni
correction for multiple comparisons was used to determine
the level of significance. A p value ,0.05 was considered
statistically significant.
RESULTS
Expression of eNOS in human neutrophils: effect of
TNF-alpha. Western blot analysis demonstrated the pres-
ence of eNOS protein in human neutrophils (Fig. 2).
Tumor necrosis factor-alpha reduced eNOS protein expres-
sion in the isolated neutrophils in a time-dependent manner
(Fig. 2). The maximal decrease in eNOS protein expression
was observed 8 h after TNF-alpha incubation (Fig. 2). At
this time, the percent neutrophil viability was 86 6 3%.
Northern blot analysis demonstrated the presence of
eNOS mRNA in human neutrophils (Fig. 3A). The post-
transcriptional regulation of eNOS mRNA was determined
in the presence of the transcriptional inhibitor DRB. Tumor
necrosis factor-alpha decreased the levels of eNOS mRNA
in a time-dependent manner in the presence of the tran-
scriptional inhibitor DRB (60 mmol/liter), indicating that
the effect of TNF-alpha on eNOS mRNA expression was
dependent on mRNA destabilization (Fig. 3, A and B).
Binding of neutrophil cytosolic proteins to the 3*-UTR
of eNOS mRNA. We first examined the ability of human
neutrophil cytoplasmic extracts to bind to a probe corre-
sponding to the entire 39-UTR by using an RNA gel
Figure 2. Representative Western blot analysis demonstrating the expres-
sion of eNOS protein in TNF-alpha–incubated (500 U/ml) human
neutrophils. Human neutrophils were incubated for different periods with
TNF-alpha (500 U/ml). (Densitometric analysis in arbitrary units—0 h:
100; 2 h: 117 6 8; 4 h: 108 6 9; 6 h: 60 6 7*; 8 h: 23 6 8*; [n 5 6];*p ,
0.05 vs. 0 h.) eNOS 5 endothelial-type nitric oxide synthase.
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mobility shift assay. Addition of human neutrophil cytosolic
extracts to the labeled UTR-L probe resulted in a gel-shift
band (Fig. 4A, lane 1). An excess of unlabeled UTR-L
(1,000 ng) prevented the interaction between labeled
UTR-L and neutrophil cytosolic extracts (Fig. 4A, lane 2).
Analysis of the nucleotide sequence of the 39-UTR of
eNOS mRNA showed two differentiated regions in its 39
terminal: an uridine plus cytidine (U 1 C)-rich region and
an adenine plus uridine (A 1 U)-rich region with two
AUUUA pentamers.
The complex between labeled UTR-L and the neutrophil
cytosolic extracts was removed by an excess of unlabeled
UTR-UC probes, but not by unlabeled UTR-AU RNA
(Fig. 4A, lanes 3 and 4). The level of prevention observed
with unlabeled UTR-UC was very similar to that obtained
when the unlabeled UTR-L RNA was the competitor,
suggesting that no additional binding site outside the
UTR-UC was present in the 39-UTR of eNOS mRNA
(Fig. 4A, lanes 2 and 3).
Treatment of neutrophil cytosolic extracts with protein-
ase K (87 mg/ml) before their incubation with labeled
UTR-L abolished the complex formation, thus indicating
the involvement of cytosolic proteins in it (Fig. 4B).
Tumor necrosis factor-alpha–induced changes in the
binding activity of human neutrophil cytosolic proteins
to the 3*-UTR of eNOS mRNA. Cytosolic extracts ob-
tained from TNF-alpha-stimulated human neutrophils
showed an increased time-dependent binding to the labeled
UTR-UC probe (Fig. 5A, lanes 2 to 5). A marked increase
in complex formation was observed after 4 h, and maximal
activity after 8 h of TNF-alpha incubation (Fig 5A, lanes 2
to 5). Tumor necrosis factor-alpha incubation of human
neutrophils for .8 h did not demonstrate any further
increase in complex formation.
Complex formation between UTR-UC and the cytosolic
proteins obtained from TNF-alpha–incubated neutrophils
was prevented by increased concentrations of unlabeled
UTR-UC (Fig. 5B). Incubation of the cytosolic extracts
obtained from TNF-alpha–stimulated neutrophils with
proteinase K also abolished complex formation with the
UTR-UC probe (data not shown).
Effect of simvastatin on the binding activity of cytosolic
proteins to eNOS mRNA. Human neutrophils were stim-
ulated with TNF-alpha (500 U/ml) for 8 h in the presence
and absence of increasing doses of simvastatin. As shown in
Figure 6, simvastatin reduced the TNF-alpha–stimulated
binding activity of neutrophil cytosolic proteins to labeled
UTR-UC. The effect of simvastatin occurred in a dose-
dependent manner (Fig. 6). A slight, although significant,
decrease of cytosolic protein binding activity was observed at
1027 mol/liter of simvastatin. Doses of simvastatin ,1027
mol/liter failed to affect the TNF-alpha–stimulated binding
activity of the neutrophil cytosolic proteins to eNOS
mRNA (data not shown). The maximal inhibition of
simvastatin on cytosolic protein binding activity was reached
at 1025 mol/liter (Fig. 6). It is noteworthy that treatment
with 1025 mol/liter of simvastatin not only reversed the
TNF-alpha–stimulated binding activity of the cytosolic
proteins to eNOS mRNA, but also caused a decrease in
binding activity with respect to that found at baseline (not
stimulated with TNF-alpha) (Fig. 6).
As occurred with the binding of the cytosolic proteins,
the presence of simvastatin (1025 mol/liter) resulted not
only in a reversal of eNOS downregulation by TNF-alpha,
but also in a significant increase in eNOS protein levels
above baseline (Fig. 7).
Endothelial-type NOS expression in neutrophils from
patients with AMI. Table 1 shows the clinical features of
the patients with AMI and control volunteers. Neutrophils
from patients with AMI showed a decreased expression of
eNOS protein, as compared with neutrophils from control
volunteers (Fig. 8A). Furthermore, in six patients with
Figure 3. A, Representative Northern blot analysis of eNOS mRNA expression after exposure of human neutrophils to TNF-alpha (500 U/ml) for different
periods. The experiments were performed in the presence of the transcriptional inhibitor DRB (60 mmol/liter). B, The graph shows the densitometric value
of the eNOS hybridization signal relative to glyceraldehyde-3-phosphate dehydrogenase, expressed as a percentage of the control value in the absence of
TNF-alpha. The GAPDH probe was used as a loading control for loading. *p , 0.05 vs. 0 h. DRB 5 5,6-dichloro-1-2-D-ribofuranosylbenzimidazole;
eNOS 5 endothelial-type nitric oxide synthase; GAPDH 5 glyceraldehyde-3-phosphate dehydrogenase.
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AMI, the expression of eNOS protein was almost unde-
tectable in their neutrophils. The reduction in the expres-
sion of eNOS protein was associated with a greater increase
(about threefold) in the complexes formed between the
neutrophil cytosolic extracts and the labeled UTR-UC
probe in the patients with AMI as compared with the
control volunteers (Fig. 8B). The interaction between
UTR-UC and the cytosolic extracts of neutrophils from
patients with AMI was prevented by an excess of unlabeled
UTR-UC (1,000 ng) and by previous incubation with
proteinase K (Fig. 8B). It is noteworthy that, although some
of the control subjects had risk factors such as cigarette
smoking, hypertension and hypercholesterolemia, in all
cases, their neutrophils showed a higher expression of
eNOS protein and a reduced presence of neutrophil cyto-
solic proteins, as compared with the neutrophils from
patients with AMI. However, the plasma levels of TNF-
alpha in the patients with AMI were not significantly
Figure 4. A, Representative gel mobility shift assay of six different
experiments with the 39-UTR of eNOS mRNA. The autoradiograph
shows the results of gel mobility shift assays using the labeled UTR-L
probe incubated with neutrophil cytosolic extracts (lane 1). Competitive
studies were performed with 1,000 ng of unlabeled UTR-L (lane 2). Two
RNA probes containing specific sequences within UTR-L were also tested
as competitors: 1,000 ng of UTR-UC (lane 3) and 1,000 ng of UTR-AU
(lane 4). The amount of the labeled UTR-L used was 1 ng. B, Treatment
of neutrophil cytosolic extracts with proteinase K (87 mg/ml) before
incubation with UTR-L RNA fully abolished the gel-shifted band.
Abbreviations as in Figure 1.
Figure 5. A, Representative gel mobility shift assay of six different
experiments to analyze the regulation of neutrophil cytosolic protein
binding activity by TNF-alpha. Human neutrophils were incubated with
TNF-alpha (500 U/ml) for different periods, and their cytosolic extracts
were analyzed by gel mobility shift assay using the labeled UTR-UC probe.
B, Competitive experiments with greater amounts of unlabeled UTR-UC
probe, demonstrating the specificity of the binding. For the competition
experiments, human neutrophils were incubated with TNF-alpha (500
U/ml) for 8 h. The amount of radiolabeled RNA used was 1 ng. 1x 5 10
ng of RNA.
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different from those found in the control volunteers (4.0 6
1.4 vs. 4.5 6 1.8 pmol/ml; p 5 NS).
DISCUSSION
Our study has shown that human neutrophils express the
eNOS isoform, and that it is reduced by TNF-alpha. We
have also shown that the cytosol of human neutrophils
contains proteins that interact with a specific sequence
within the 39-UTR of eNOS mRNA. The binding activity
of these cytosolic proteins was markedly enhanced by the
stimulation of neutrophils with TNF-alpha.
Endothelial-type NOS expression in human neutrophils:
regulation by TNF-alpha. Functional studies have dem-
onstrated the ability of neutrophils to produce NO through
constitutively expressed NOS (15,16,24,25). We have dem-
onstrated, at the molecular level, the presence of an
endothelial-like NOS in human neutrophils.
Expression of eNOS has been identified not only in the
endothelium, but also in other blood cells, including mono-
cytes and macrophages (26,27). The purity of our neutrophil
preparations excludes the possibility of the presence of
eNOS from contaminating macrophages.
In contrast with our results, Amin et al. (28) recently
reported that human neutrophils constitutively expressed
the iNOS isoform. Furthermore, Yan et al. (29) could not
find detectable amounts of eNOS in neutrophils. The
presence of iNOS expression and the lack of eNOS expres-
sion reported in the aforementioned studies could be due to
the presence of endotoxins contained in the incubation
medium, because these investigators did not report the
use of endotoxin-free conditions in their experiments. In
this regard, we recently reported a downregulation of
eNOS expression in conditions in which iNOS protein is
upregulated (30). In our study, all of the experimental
procedures were performed under sterile and endotoxin-
free conditions.
Expression of eNOS mRNA was found to be decreased
after TNF-alpha stimulation in the presence of DRB, a
transcriptional inhibitor (31), strongly suggesting that a
change in stability of the eNOS message is the predominant
mechanism for the downregulation of eNOS expression by
TNF-alpha.
Several proteins that bind to specific sequences in the
39-UTR of many mRNAs have been implicated in the
regulation of their half-lives (12,13). In a previous study, we
have demonstrated that bovine endothelial cytosolic pro-
teins interact with the 39-UTR of eNOS mRNA (14). In
the present study, complexes were formed between the
cytosolic lysates of human neutrophils and the complete in
vitro–transcribed 39-UTR of eNOS mRNA. The proteinase
K preincubation assay demonstrated that the neutrophil
cytosolic components that bind to the 39-UTR of eNOS
mRNA were proteins. In addition, the gel-shifted analysis
demonstrated that the cytosolic proteins bind to an U 1
C–rich region in this 39-UTR of eNOS mRNA. In this
regard, although the AUUUA pentamer is a common
Figure 6. Representative gel mobility shift assay of six different experi-
ments to test the effect of simvastatin on the binding activity of human
neutrophil cytosolic proteins to the 39-UTR of eNOS mRNA. The
neutrophils were stimulated with TNF-alpha (500 U/ml) for 8 h in the
presence and absence of increasing doses of simvastatin. The cytosolic
extracts were analyzed using the labeled UTR-UC probe. (Densitometric
analysis in arbitrary units—basal: 100; TNF-alpha: 180 6 10; TNF-
alpha 1 simvastatin 1027 mol/liter: 142 6 17*; TNF-alpha 1 simvastatin
1026 mol/liter: 120 6 9*; TNF-alpha 1 simvastatin 1025 mol/liter: 45 6
7*; [n 5 6];*p , 0.05 vs. TNF-alpha–incubated neutrophils.) Abbrevia-
tions as in Figure 1.
Figure 7. Representative Western blot analysis demonstrating the effect of
simvastatin (1025 mol/liter) on eNOS expression in TNF-alpha–
stimulated (500 U/ml) human neutrophils. Expression of eNOS was
determined 8 h after TNF-alpha stimulation. (Densitometric analysis in
arbitrary units—basal: 100*; TNF-alpha: 23 6 8; TNF-alpha 1 simva-
statin 1025 mol/liter: 211 6 19*; [n 5 6]; *p , 0.05 vs. TNF-alpha–
incubated neutrophils.) eNOS 5 endothelial-type nitric oxide synthase.
Table 1. Characteristics of the Study Group
Control Group
(n 5 8)
AMI Group
(n 5 8)
Age in years (range) 57.1 (33–70) 57.4 (39–80)
Men/women, n 5/3 7/1
Risk factors, n (%)
Smoker 3 (37.5%) 6 (75%)
Hypertension 1 (12.5%) 4 (50%)
Hypercholesterolemia
(total cholesterol .200 mg/dl)
3 (37.5%) 3 (37.5%)
Diabetes mellitus — —
Previous coronary events — —
Medication on admission
Beta-blockers — 1 (12.5%)
Calcium antagonists — 2 (25%)
ACE inhibitors — 2 (25%)
Diuretics — 1 (12.5%)
ACE 5 angiotensin-converting enzyme; AMI 5 acute myocardial infarction.
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sequence that binds proteins within the 39-UTR, different
studies have demonstrated proteins that interact with the
39-UTR of mRNAs independently of these AUUUA se-
quences (32).
Our next aim was to analyze whether the binding of
neutrophil cytosolic extracts to the 39-UTR of eNOS mRNA
could be modified by TNF-alpha. Cytosolic extracts obtained
from TNF-alpha–stimulated human neutrophils showed in-
creased binding to the U 1 C–rich region of the 39-UTR of
eNOS mRNA, an effect that was associated with a decreased
level of eNOS protein and eNOS mRNA.
Simvastatin and eNOS protein expression in neutro-
phils. In an attempt to study the correlation between the
binding of neutrophil cytosolic proteins to eNOS mRNA
and the level of expression of the eNOS protein, we
performed experiments in the presence of simvastatin, a
drug that has been previously reported to stabilize eNOS
mRNA in the endothelium (10,11). Simvastatin prevented
the binding of neutrophil cytosolic proteins to eNOS
mRNA stimulated by TNF-alpha. This was accompanied
by an increased expression of eNOS protein, suggesting an
association between the binding of cytosolic proteins to the
39-UTR of eNOS mRNA and the decrease in eNOS
protein expression.
The levels of simvastatin that prevented eNOS protein
expression in TNF-alpha–stimulated neutrophils are within
the range of the expected tissue levels obtained with
recommended doses (33). It is noteworthy that the binding
region of the neutrophil cytosolic proteins flanks a potential
stem-loop structure in the 39-UTR of eNOS mRNA.
Therefore, the binding of these cytosolic proteins to the
39-UTR may modify the tri-dimensional conformation of
this region, showing a RNase active site. A similar mecha-
nism has been described for iron-regulated transferrin re-
ceptor mRNA stability (34).
Reduction of eNOS protein expression in patients with
AMI. To analyze the in vivo reproduction of the in vitro
findings, we obtained neutrophils from patients with AMI.
Neutrophils obtained from patients with AMI showed a
significant reduction of eNOS protein, accompanied by
increased binding of the cytosolic extracts to the 39-UTR of
eNOS mRNA, suggesting a relationship between these two
phenomena.
Interestingly, the expression of eNOS protein in neutro-
phils from patients with AMI was markedly lower than that
observed with in vitro TNF-alpha incubation. In this
regard, we did not find modifications in the TNF-alpha
plasma levels between patients with AMI and control
volunteers, as previously reported (19,35). However, al-
though we recognize that the number of the study subjects
could be not enough to find such differences, Guille´n et al.
(36) have also reported that other cytokines (i.e.,
interleukin-1-beta and interleukin-6), but not TNF-alpha,
are increased during the early phase of myocardial infarc-
tion. However, we could not rule out the possibility that
other cytokines generated during AMI (35,37), in addition
to TNF-alpha, could contribute to the reduction in eNOS
expression in neutrophils.
Impairment in the production of endothelium-derived
NO has been extensively described in patients with acute
coronary syndromes (38,39), but the expression of con-
stitutively expressed NOS in neutrophils of patients with
AMI had not been determined. Nitric oxide produced in
neutrophils through constitutively expressed NOS ap-
pears to have a relevant role in inhibiting platelet activa-
tion and leukocyte adhesion to the endothelium (6,17,18).
In addition, infusion of either organic NO donors or NO
itself provides cardioprotective effects related to the
inhibition of neutrophil activity (40,41). In light of this
new information, further studies are needed to analyze the
actual relevance of the decreased eNOS protein expression
in neutrophils for the detrimental role currently conferred to
these cells in the setting of AMI.
Conclusions. The present results demonstrate that human
neutrophils express eNOS, which is downregulated by TNF-
Figure 8. A, Representative Western blot analysis showing eNOS protein
expression in neutrophils obtained from a patient with AMI and from a
control subject. (Densitometric analysis in arbitrary units—control subject:
100; patient with AMI: 16 6 4 [n 5 8]; *p , 0.05.) B, Representative gel
mobility shift assay to analyze the presence of the cytosolic proteins that
bind to 39-UTR of eNOS mRNA in neutrophils from both a control
subject and a representative patient with AMI. Competitive experiments
were performed with 1,000 ng of unlabeled UTR-UC demonstrating the
specificity of the binding. Treatment of the neutrophil cytosolic extracts
from patients with AMI with proteinase K (Prot K, 87 mg/ml) before
incubation with the UTR-L RNA fully abolished the gel-shifted band.
39-UTR 5 39-untranslated region; AMI 5 acute myocardial infarction.
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alpha and during AMI. This effect was associated with
increased binding activity of neutrophil cytosolic proteins to
the 39-UTR of eNOS mRNA. The protection of eNOS
expression in neutrophils may be a suitable target for therapy.
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